Path: /organizations/cognicann
Type: Biotechnology Company
Headquarters: Vancouver, British Columbia, Canada
Founded: 2015
Cognicann is a Canadian biotechnology company headquartered in Vancouver, British Columbia, focused on developing innovative therapies for neurodegenerative diseases, with an emphasis on Alzheimer's disease and cognitive impairment. The company leverages novel small molecule therapeutic approaches to target disease mechanisms underlying cognitive decline.
The global Alzheimer's disease therapeutic market represents one of the largest unmet medical needs in healthcare, with over 55 million people living with dementia worldwide and an estimated annual cost exceeding $1.3 trillion[1]. Cognicann positions itself within this landscape by developing disease-modifying treatments that target multiple pathological pathways simultaneously[2].
Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of all dementia cases[1:1]. The disease is characterized by two hallmark pathological features: extracellular amyloid-beta (Aβ) plaques composed of Aβ peptides derived from amyloid precursor protein (APP) processing, and intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein[3].
Cognicann focuses on developing disease-modifying treatments for Alzheimer's Disease, targeting key pathological pathways including[2:1][3:1]:
The company's research also addresses age-related cognitive impairment and other forms of dementia where small molecule interventions may restore or protect cognitive function[1:2]. Beyond Alzheimer's disease, Cognicann's platform may have applications in:
Cognicann employs rational drug design and high-throughput screening to identify novel small molecule candidates that can[7]:
Cognitive function depends on proper neurotransmission across multiple systems:
The company develops small molecules targeting toxic protein aggregates[2:2][3:2]:
Neuroinflammation is both a consequence and driver of neurodegeneration[6:1][11]:
Synaptic loss is the strongest correlate of cognitive decline in AD[7:1][11:1]:
Cognicann's drug discovery platform employs multiple complementary approaches:
The company maintains libraries of novel small molecules and natural product extracts for screening:
Lead compounds undergo systematic optimization for:
Cognicann's therapeutic pipeline addresses multiple stages of Alzheimer's disease progression:
CGC-100 is Cognicann's lead clinical candidate for Alzheimer's disease:
CGC-200 is a second-generation compound targeting neuroinflammation:
CGC-300 represents early-stage research on novel targets including insulin signaling[16] and metal ion homeostasis[17]:
Cognicann's clinical development approach includes:
The company integrates biomarkers throughout clinical development:
Recognizing the multi-pathology nature of AD, Cognicann explores:
The company leverages:
Cognicann has established research partnerships with Canadian academic institutions and has received funding from provincial and federal research programs supporting biotechnology innovation in Canada:
Cognicann operates within the Vancouver biotech ecosystem, which includes[18][19]:
Cognicann competes with other companies developing AD therapeutics:
Cognicann differentiates itself through:
While specific financial details are proprietary, Cognicann's funding comes from:
Cognicann's long-term strategy includes:
Cognicann's research pipeline also explores emerging areas of AD biology:
Recent research reveals significant connections between gut microbiota and brain health[20]. The company investigates:
DNA methylation, histone modifications, and non-coding RNAs play roles in AD pathogenesis[21]. Cognicann explores:
Dysregulation of copper, zinc, and iron contributes to oxidative stress and amyloid aggregation[17:1]. Research approaches include:
Insulin resistance and glucose metabolism dysfunction are increasingly recognized in AD[16:1]. Cognicann's metabolic research includes:
Alzheimer's Disease Facts and Figures. Alzheimer's Association. 2024. ↩︎ ↩︎ ↩︎
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress but problems. Science. 2002. ↩︎ ↩︎ ↩︎
Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011. ↩︎ ↩︎ ↩︎
Vassar R, Kandalepas PC. The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther. 2011. ↩︎
De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer's disease. Cold Spring Harb Perspect Med. 2012. ↩︎
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015. ↩︎ ↩︎ ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎ ↩︎
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999. ↩︎
Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: an overview. Drug Discov Today. 2007. ↩︎ ↩︎
Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease and the need for complementary therapies. Nat Rev Neurol. 2011. ↩︎
Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener. 2011. ↩︎
Mattson MP. Mitochondria and disease: a central role for defective ion motive ATPases. Nat Rev Neurosci. 2020. ↩︎
Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in Alzheimer's disease. Proc Natl Acad Sci USA. 2009. ↩︎
Molokanova E, Savonenko AV. From translational challenges to integrative drug development: the path to effective treatments for Alzheimer's disease. J Prev Alzheimers Dis. 2023. ↩︎
Craft S, Stennis Watson G. Insulin and neurodegenerative disease: a connection for disease modification?. Behav Brain Res. 2004. ↩︎ ↩︎
Bush AI, Tanzi RE. The galvanic role of metal ions in the pathogenesis of Alzheimer's disease. Mol Psychiatry. 2008. ↩︎ ↩︎
Canadian Biotechnology Industry Report. Canada's Biotechnology Industry Organization. 2024. ↩︎
British Columbia Biotechnology Industry Profile. BC Tech Association. 2024. ↩︎
Kowalski K, Mulak M. Brain-gut-microbiota axis in Alzheimer's disease. Dig Dis. 2019. ↩︎
Coppola G, Chinnathambi S. Epigenetic mechanisms in Alzheimer's disease: from genes to environment. Nat Rev Neurol. 2022. ↩︎